Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.
The U.S. FDA approved Johnson & Johnson’s nasal spray antidepressant Spravato for people resistant to other treatments, but placed restrictions on use of the drug.
Americans suffering from a “vacation deficit” are nearly two times as likely to show signs of moderately severe to severe depression compared to the national average, according to the 10th annual Allianz Global Assistance Vacation Confidence Index.
A new study in the journal The BMJ finds that the risk of intracranial hemorrhage – bleeding that occurs in or around the brain – is increased when one combines […]
Two brothers – one an entrepreneur, the other a Columbia University psychiatrist – are claiming today that a new combination of experimental medicines may prevent suicidal thoughts in people with […]
R&D efforts on the part of major biopharmaceutical companies for novel drugs to treat depression and other CNS diseases have eroded over the past decade. In fact, a study published […]
